Table 4.
Multiple logistic regression model for risk of DLT
| Myelosuppressive agents |
Nonmyelosuppressive agents |
|||
|---|---|---|---|---|
| Variable | OR | 95% CI | OR | 95% CI |
| Age | 1.0 | (0.9–1.2) | 1.0 | (0.9–1.1) |
| n of concomitant medications | 1.0 | (0.7–1.3) | 0.9 | (0.6–1.3) |
| Drug dosea | 93.9b | (4.2–2114) | 34.0b | (1.9–595) |
| n of prior regimens | 1.0 | (0.6–1.4) | 1.1 | (0.8–1.5) |
| Gender | ||||
| Male | 1.0 | - | 1.0 | - |
| Female | 10.1b | (2.3–44.8) | 0.8 | (0.2–2.5) |
| Prior radiation | ||||
| None | 1.0 | - | 1.0 | - |
| Yes | 9.3b | (1.6–54.8) | 1.2 | (0.2–6.7) |
| ECOG performance status score | ||||
| 0 | 1.0 | - | 1.0 | - |
| 1 or 2 | 0.6 | (0.2–1.6) | 3.4b | (1.3–8.8) |
| Prior transplant | ||||
| None | 1.0 | - | 1.0 | - |
| Yes | 1.9 | (0.2–21) | 1.4 | (0.4–5.2) |
| Narcotic use | ||||
| None | 1.0 | - | 1.0 | - |
| Yes | 3.7 | (0.6–22) | 0.8 | (0.1–4.9) |
a
Dose is expressed as a fraction of the MTD.
b
Significant at <5% significance level.
Abbreviations: CI, confidence interval; DLT, dose-limiting toxicity; ECOG, Eastern Cooperative Oncology Group; MTD, maximum-tolerated dose; OR, odds ratio.